They developed hybrid molecules that combine chloroquine’s metal ion chelating framework with critical binding site fragments from the known PDE4 inhibitors Rolipram and Roflumilast, both of which have been studied in preclinical AD models (Maramai et al., 2022). Here, PDE4A is linked to Alzheimer disease.